Brepocitinib (PF-06700841): A Comprehensive Monograph on a Novel Dual TYK2/JAK1 Inhibitor

Executive Summary

Brepocitinib (PF-06700841) is an orally available, investigational small molecule that represents a targeted therapeutic approach to immunomodulation through the dual inhibition of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1). This mechanism is designed to provide broad-spectrum suppression of key pro-inflammatory cytokine signaling pathways implicated in a wide range of autoimmune and inflammatory diseases. Developed initially by Pfizer and now being advanced by Priovant Therapeutics, Brepocitinib has undergone one of the most extensive Phase 2 clinical programs for a drug of its class, demonstrating consistent and potent clinical activity across numerous distinct disease states.

Pharmacologically, Brepocitinib is a potent inhibitor of its target kinases, with half-maximal inhibitory concentrations (IC50​) of 23 nM for TYK2 and 17 nM for JAK1. However, its selectivity against Janus Kinase 2 (JAK2) is modest (IC50​ = 77 nM), suggesting that at clinically relevant doses, significant JAK2 inhibition is likely. This profile results in a safety and tolerability signature that is largely consistent with the broader JAK inhibitor class, including risks of serious infections and laboratory parameter changes, without offering a clear differentiation from first-generation agents. The drug's pharmacokinetic profile is favorable for oral administration, characterized by rapid and nearly complete absorption, high bioavailability (~75%), and clearance primarily through hepatic metabolism.

The clinical development trajectory of Brepocitinib serves as a compelling case study in pharmaceutical asset strategy. Despite generating statistically significant and clinically meaningful efficacy data in Phase 2 trials for large-market indications—including psoriatic arthritis, plaque psoriasis, ulcerative colitis, alopecia areata, and hidradenitis suppurativa—development in these areas was discontinued. This strategic decision appears driven by a commercial assessment that the drug's risk-benefit profile, particularly its safety signature, was not sufficiently differentiated to compete effectively in these crowded therapeutic landscapes.

Following its out-licensing to Priovant Therapeutics, Brepocitinib's development was strategically repositioned to focus on severe orphan and specialty autoimmune diseases with high unmet medical need, where its potent efficacy may outweigh its class-associated risks. The current lead indications are Dermatomyositis (DM) and Non-Infectious Uveitis (NIU). The ongoing Phase 3 VALOR study in DM is the largest interventional trial ever conducted for the disease, and the program in NIU has received Fast Track Designation from the U.S. Food and Drug Administration. A large Phase 2 trial in Systemic Lupus Erythematosus (SLE) was terminated after failing to meet its primary endpoint, a result attributed to an unprecedentedly high placebo response rate rather than a lack of drug activity.

In conclusion, Brepocitinib is a highly active immunomodulatory agent whose therapeutic potential is undeniable. Its future, however, is not defined by its broad efficacy but by the strategic precision with which it is being developed. The pivot to orphan indications represents a calculated effort to align its potent mechanism and established risk profile with patient populations for whom the therapeutic need is greatest and the competitive bar is more attainable. The upcoming results from the Phase 3 programs in Dermatomyositis and Non-Infectious Uveitis, expected in 2025 and beyond, will be the definitive determinants of Brepocitinib's ultimate clinical and commercial success.

1.0 Introduction: Brepocitinib - A New Paradigm in Autoimmune Disease Modulation

1.1 The Janus Kinase (JAK) Pathway in Autoimmunity

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is a pivotal intracellular signaling cascade that governs cellular responses to a wide array of extracellular signals, most notably cytokines and growth factors.[1] This pathway is fundamental to the regulation of hematopoiesis, immunity, and inflammation.[2] The JAK family comprises four non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and Tyrosine Kinase 2 (TYK2). When a cytokine binds to its specific cell-surface receptor, it induces the dimerization of receptor subunits, bringing the associated JAKs into close proximity. This allows for their trans-phosphorylation and activation. The activated JAKs then phosphorylate specific tyrosine residues on the intracellular domain of the receptor, creating docking sites for STAT proteins. Once recruited, STATs are themselves phosphorylated by the JAKs, leading to their dimerization, translocation to the nucleus, and subsequent modulation of target gene expression.[1]

In the context of autoimmune diseases, this pathway is frequently dysregulated. A multitude of pro-inflammatory cytokines, which are central to the pathophysiology of conditions like psoriasis, psoriatic arthritis, and inflammatory bowel disease, rely on the JAK-STAT pathway to exert their effects.[1] Consequently, the JAK family of kinases has emerged as a highly validated and druggable target class for therapeutic intervention. By inhibiting one or more JAKs, it is possible to disrupt the signaling of pathogenic cytokines, thereby reducing inflammatory responses and preventing the tissue damage characteristic of these chronic conditions.[2]

1.2 Rationale for Dual TYK2/JAK1 Inhibition

The four JAK family members have distinct but overlapping roles in mediating cytokine signals. Different cytokine receptors pair with specific combinations of JAKs to initiate downstream signaling. This specificity provides a strong rationale for developing inhibitors with varying selectivity profiles to target particular pathogenic pathways.[1]

Tyrosine Kinase 2 (TYK2) is a critical component of the signaling complexes for key cytokines involved in Th1 and Th17 cell differentiation and function, including interleukin-12 (IL-12) and interleukin-23 (IL-23).[1] Furthermore, TYK2 is essential for the signaling of Type I interferons (IFNs), a cytokine family deeply implicated in the pathogenesis of diseases like systemic lupus erythematosus and dermatomyositis.[1]

Janus Kinase 1 (JAK1) plays an equally crucial role, partnering with JAK3 to mediate signals from cytokines that use the common gamma chain (γc​) receptor subunit, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.[1] JAK1 is also involved in signaling for the IL-6 family of cytokines and, like TYK2, is required for Type I IFN signaling.[1]

The development of Brepocitinib was founded on the hypothesis that simultaneously inhibiting both TYK2 and JAK1 could provide broader and potentially more profound immunomodulation than targeting either kinase in isolation.[1] Such a dual-inhibition strategy aims to block a wider spectrum of pathogenic cytokine pathways. For example, by inhibiting both kinases, Brepocitinib can potently suppress the signaling of IL-12, IL-23, and Type I IFNs (via TYK2), as well as IL-6 and the

γc​ cytokines (via JAK1).[6] This comprehensive blockade of multiple inflammatory axes was theorized to offer superior efficacy in complex autoimmune diseases where numerous cytokine families contribute to the disease process.[1]

1.3 Overview of Brepocitinib as a First-in-Class Investigational Agent

Brepocitinib, also known by its development code PF-06700841, is an orally available, small molecule drug designed to be a selective, dual inhibitor of TYK2 and JAK1.[2] It emerged from a dedicated discovery program at Pfizer aimed at creating a therapeutic agent that could leverage the synergistic potential of targeting these two specific kinases for the treatment of autoimmune diseases.[1]

As an investigational agent, Brepocitinib has been evaluated in one of the most extensive clinical development programs for a molecule in its class. It has been studied in a wide array of autoimmune and inflammatory conditions, including plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease, alopecia areata, hidradenitis suppurativa, atopic dermatitis, systemic lupus erythematosus, dermatomyositis, and non-infectious uveitis.[2] This broad investigation reflects the foundational scientific premise that its dual mechanism of action could be applicable across a wide spectrum of immunologically-driven pathologies. The journey of Brepocitinib through clinical development, including its strategic repositioning from large-market indications to orphan diseases, provides a compelling narrative of modern pharmaceutical R&D strategy, which will be explored in detail in this report.

2.0 Molecular Profile and Physicochemical Properties

2.1 Chemical Structure and Identification

Brepocitinib is a synthetic organic compound classified as a small molecule.[2] Its precise chemical structure is defined by its International Union of Pure and Applied Chemistry (IUPAC) name:

-pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone.[2] This complex name describes a molecule built around a central 3,8-diazabicyclo[3.2.1]octane scaffold, which is functionalized with a pyrimidine ring linked to a methyl-pyrazole group on one side, and a 2,2-difluorocyclopropyl methanone group on the other. Other systematic names, such as

methanone, ((1S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-, are also used in various chemical registries.[2]

For computational and database purposes, the molecule is represented by standardized chemical identifiers. Its Simplified Molecular Input Line Entry System (SMILES) string is CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F, which encodes its two-dimensional structure and stereochemistry.[2] The International Chemical Identifier (InChI) and its hashed version, the InChIKey (

BUWBRTXGQRBBHG-MJBXVCDLSA-N), provide a unique and canonical representation of the compound's structure, ensuring its unambiguous identification across different chemical databases and literature sources.[2] A comprehensive list of its key identifiers is provided in Table 1.

2.2 Key Physicochemical Characteristics and Formulation Considerations

The fundamental physicochemical properties of Brepocitinib are critical determinants of its behavior as a pharmaceutical agent, influencing its absorption, distribution, formulation, and overall "drug-like" characteristics. The molecular formula of Brepocitinib is C18​H21​F2​N7​O, and it has a molar mass of 389.411 g·mol⁻¹.[2]

Brepocitinib has been developed in multiple formulations to suit different therapeutic applications. For systemic treatment of autoimmune diseases, it is formulated as an oral tablet.[15] The drug is often used in its tosylate salt form (

C_{18}H_{21}F_{2}N_{7}O · C_{7}H_{8}O_{3}S), which can improve the stability and handling properties of the active pharmaceutical ingredient.[17] The development of an oral formulation was supported by the molecule's favorable intrinsic properties, including high aqueous solubility and high passive permeability, which are predictive of good absorption from the gastrointestinal tract and contribute to its high oral bioavailability.[19] The drug is soluble in organic solvents like dimethyl sulfoxide (DMSO) and ethanol but is reported as insoluble in water, though its aqueous solubility is sufficient for absorption at physiological pH.[20]

In addition to the oral formulation, a topical cream has been developed for the treatment of dermatological conditions such as atopic dermatitis and plaque psoriasis.[15] This allows for localized delivery of the drug to the skin, aiming to maximize therapeutic effect at the site of inflammation while minimizing systemic exposure and associated side effects.

Property	Value	Source(s)
Common Name	Brepocitinib	2
Development Code	PF-06700841	2
DrugBank ID	DB15003	2
CAS Number	1883299-62-4	2
IUPAC Name	-pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone	2
Molecular Formula	C18​H21​F2​N7​O	2
Molar Mass	389.411 g·mol⁻¹	13
SMILES String	CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F	2
InChIKey	BUWBRTXGQRBBHG-MJBXVCDLSA-N	2
Drug Type	Small Molecule	2
Solubility	Soluble in DMSO, Ethanol; Insoluble in Water	20
Table 1: Key Identifiers and Physicochemical Properties of Brepocitinib

3.0 Mechanism of Action and In-Depth Pharmacodynamics

3.1 Selective Inhibition of TYK2 and JAK1 Kinases

Brepocitinib functions as a potent, orally available, and selective inhibitor of two members of the Janus kinase family: non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1.[2] Its mechanism of inhibition is classified as Type 1, meaning it acts as an ATP-competitive inhibitor.[1] It binds to the highly conserved ATP-binding pocket within the catalytic domain of the kinases, preventing the binding of ATP and thereby blocking the phosphotransferase activity essential for kinase function. By occupying this site, Brepocitinib effectively shuts down the kinase's ability to phosphorylate itself and its downstream substrates, thus disrupting the entire signaling cascade initiated by cytokine receptor activation.[1] This direct, competitive inhibition is the molecular basis for its immunomodulatory and anti-inflammatory effects.[2]

3.2 Potency, Selectivity, and In Vitro Activity Profile

The pharmacological profile of a kinase inhibitor is defined by its potency against its intended targets and its selectivity against other related kinases. Brepocitinib was designed to potently inhibit TYK2 and JAK1 while sparing other JAK family members, particularly JAK2, to mitigate potential safety concerns.[1]

In cell-free enzymatic assays, which measure the direct interaction between the drug and the isolated kinase, Brepocitinib demonstrates high potency against its primary targets. The half-maximal inhibitory concentration (IC50​), a measure of the drug concentration required to inhibit 50% of the enzyme's activity, was determined to be 17 nM for JAK1 and 23 nM for TYK2.[8]

The selectivity of Brepocitinib within the JAK family is a critical aspect of its design. The drug exhibits a degree of selectivity against JAK2, with an IC50​ of 77 nM.[8] Its activity against JAK3 is significantly weaker, with a reported

IC50​ of 6.49 μM (6490 nM), indicating substantial selectivity against this kinase.[8] The stated goal of the discovery program was to achieve "appropriate in-family selectivity against JAK2 and JAK3".[19] However, the quantitative data reveals a relatively narrow selectivity window between the primary targets and JAK2. The

IC50​ for JAK2 is only approximately 4.5-fold higher than that for JAK1 and 3.3-fold higher than for TYK2. This modest degree of selectivity suggests that at drug concentrations sufficient to achieve near-complete inhibition of JAK1 and TYK2 in a clinical setting, a substantial degree of JAK2 inhibition is also likely to occur. This has important implications for the drug's safety profile, as JAK2 is critically involved in hematopoietic signaling, and its inhibition is associated with effects such as anemia and thrombocytopenia. The drug's profile is therefore more akin to a pan-JAK inhibitor with a preference for TYK2/JAK1, rather than a truly selective agent that completely spares JAK2.

3.3 Impact on Pro-Inflammatory Cytokine Signaling Pathways

The ultimate therapeutic effect of Brepocitinib is derived from its ability to disrupt cytokine signaling in a cellular context. This has been extensively characterized using human whole blood (HWB) assays, which provide a more physiologically relevant measure of the drug's functional activity by assessing the inhibition of STAT phosphorylation downstream of cytokine stimulation.[8]

These assays confirm that Brepocitinib potently blocks the signaling of cytokines that rely on TYK2 and/or JAK1. This includes:

• Type I Interferon Pathway: Brepocitinib potently inhibits IFNα-induced STAT3 phosphorylation (a TYK2/JAK1-dependent process) with an IC50​ of 30 nM.[22] This potent blockade of Type I IFN signaling provides a strong mechanistic rationale for its investigation in interferon-driven diseases such as dermatomyositis and systemic lupus erythematosus, where this pathway is a key driver of pathology.[6]
• IL-12/IL-23 Pathways: The drug effectively inhibits signaling from IL-12 (measured by pSTAT4) and IL-23 (measured by pSTAT3), with HWB IC50​ values of 65 nM and 120 nM, respectively.[8] As these pathways are central to the pathogenesis of psoriasis and psoriatic arthritis, this activity underpins its efficacy in those conditions.
• IL-6 Pathway: Brepocitinib demonstrates good potency against IL-6-induced pSTAT1 signaling in T-cells, with an IC50​ of 81 nM.[8]
• γ-common Chain Cytokine Pathways: Signaling by cytokines like IL-15 (measured by pSTAT5), which are dependent on JAK1/JAK3, is also inhibited with reasonable potency (IC50​ = 238 nM).[8]
• JAK2-dependent Pathways: As predicted by the enzymatic assay data, Brepocitinib shows weaker activity against pathways that are primarily JAK2-dependent. The inhibition of erythropoietin (EPO)-induced pSTAT5 signaling (a JAK2 homodimer process) in progenitor cells occurs with an IC50​ of 577 nM, confirming its relative but not absolute selectivity against JAK2-mediated signaling.[8]

A summary of these key potency values is presented in Table 2.

Target Kinase / Pathway	Assay Type	IC50​ (nM)	Source(s)
JAK1	Cell-free	17	7
TYK2	Cell-free	23	7
JAK2	Cell-free	77	8
JAK3	Cell-free	6,490	8
IFNα/pSTAT3	Human Whole Blood	30	22
IL-12/pSTAT4	Human Whole Blood	65	8
IL-6/pSTAT1	Human Whole Blood	81	8
IL-27/pSTAT3	Human Whole Blood	86	8
IL-23/pSTAT3	Human Whole Blood	120	8
IL-15/pSTAT5	Human Whole Blood	238	8
EPO/pSTAT5	Human Whole Blood	577	8
Table 2: In Vitro and Cellular Potency of Brepocitinib Against JAK Family Kinases and Key Cytokine Pathways

4.0 Comprehensive Pharmacokinetic Profile (ADME)

The pharmacokinetic (PK) profile of a drug describes its absorption, distribution, metabolism, and excretion (ADME), which collectively determine the concentration of the drug in the body over time. Brepocitinib has been characterized in multiple Phase 1 studies in healthy volunteers, including a dedicated ADME study using a ¹⁴C-microtracer approach, as well as through population PK modeling incorporating data from patients with various autoimmune diseases.[16]

4.1 Absorption and Bioavailability

Following oral administration, Brepocitinib is absorbed rapidly from the gastrointestinal tract.[21] Population PK modeling indicates a first-order absorption process with a rapid absorption rate constant (

ka​) of 3.46 h⁻¹ and a minimal absorption lag time of 0.24 hours for the tablet formulation.[16] This is consistent with a median time to maximum plasma concentration (

Tmax​) of one hour or less observed in clinical studies.[16]

The extent of absorption is very high. A study using an intravenous ¹⁴C-microdose alongside an oral dose determined that the fraction of the oral dose absorbed from the intestine (Fa​) is essentially complete, at approximately 106.9%.[16] Despite this complete absorption, the absolute oral bioavailability (

F), which represents the fraction of the oral dose that reaches systemic circulation unchanged, is approximately 74.6%.[16] The discrepancy between the high

Fa​ and the lower F suggests that Brepocitinib undergoes some degree of first-pass metabolism in the gut wall or liver before reaching the systemic circulation.

A clinically significant food effect has been identified. Co-administration of Brepocitinib with a high-fat meal leads to a substantial reduction in both the rate and extent of absorption. The rate of absorption is decreased by 69.9%, and the total drug exposure (AUC) is reduced by 28.3%.[16] This finding implies that for consistent and predictable drug exposure, dosing should be standardized with respect to meals, a critical instruction for clinical practice and patient labeling.

4.2 Distribution

Brepocitinib exhibits extensive distribution throughout the body. The population PK model estimated a large apparent volume of distribution (Vd​/F) of 136 L.[16] This value, which significantly exceeds the volume of total body water, indicates that the drug does not remain confined to the bloodstream but distributes widely into peripheral tissues and organs.[26] This is consistent with its intended mechanism of action, which requires reaching intracellular targets in various tissues affected by autoimmune processes. The drug is not highly bound to plasma proteins, with a fraction unbound of 0.61, meaning a substantial portion of the drug in circulation is free to distribute into tissues and exert its pharmacological effect.[16]

4.3 Metabolism

The primary route of elimination for Brepocitinib is through hepatic metabolism.[21] Studies indicate that this process is predominantly mediated by the cytochrome P450 (CYP) family of enzymes. The major contributors to its hepatic metabolism are CYP3A4/5 (accounting for 77% of metabolism) and CYP1A2 (14%).[16] The parent drug, Brepocitinib, is the major circulating species in plasma (47.8% of drug-related material). A major, but pharmacologically inactive, monohydroxylated metabolite (M1) is also present in significant concentrations (37.1%).[16]

4.4 Excretion and Clearance

Following metabolism, the resulting metabolites are primarily excreted via the kidneys. A human mass balance study showed that after a single oral dose of ¹⁴C-labeled Brepocitinib, a total of 96.7% of the administered radioactivity was recovered over the collection period.[21] The vast majority of this recovery was in the urine (88.0%), with a smaller portion found in the feces (8.7%).[21] Importantly, the urinary excretion of unchanged, parent Brepocitinib was minor, accounting for only about 6.0% of the oral dose.[21] This confirms that renal clearance of the parent drug is not a major elimination pathway and that metabolic clearance is the dominant process.

The apparent total body clearance (CL/F) from the population PK model was estimated to be 18.7 L/h.[16] The elimination half-life (

T1/2​) is reported to be in the range of 3.8 to 10.7 hours across single and multiple dose studies, supporting a once-daily dosing regimen.[16]

4.5 Population Pharmacokinetics and Covariate Effects

Population PK modeling, which integrates data from a large and diverse group of individuals, has identified several factors (covariates) that significantly influence Brepocitinib's disposition.[16]

One of the most significant findings is an ethnic difference in clearance. Asian populations were found to have a 24.3% lower clearance compared to non-Asian populations, even after accounting for differences in body weight.[16] A lower clearance rate leads to higher drug exposure (AUC). This is a substantial effect that could increase the risk of concentration-dependent adverse events in this population and may necessitate dose adjustments or more careful monitoring in clinical practice.

The analysis also revealed evidence of nonlinear pharmacokinetics at high doses. At doses of 175 mg and above, the relative bioavailability was found to be 35.1% higher than at lower doses.[16] The mechanism for this dose-dependent increase in bioavailability has not been fully elucidated but could be related to the saturation of first-pass metabolic pathways at high concentrations.

Parameter	Value	Source(s)
Apparent Clearance (CL/F)	18.7 L/h	16
Apparent Volume of Distribution (Vd​/F)	136 L	16
Absolute Bioavailability (F)	~75%	16
Fraction Absorbed (Fa​)	~107%	16
Absorption Rate Constant (ka​)	3.46 h⁻¹	16
Effect of High-Fat Meal	Rate (ka​) ↓ 69.9%; Extent (AUC) ↓ 28.3%	16
Effect of Asian Ethnicity	Clearance (CL/F) ↓ 24.3%	16
Table 3: Summary of Human Pharmacokinetic Parameters for Oral Brepocitinib

5.0 Clinical Development Program: A Strategic Trajectory

5.1 Origination and Early Development by Pfizer

Brepocitinib was discovered and initially developed by Pfizer as part of a strategic effort to create a novel, orally administered immunomodulator for autoimmune diseases.[1] The program was built on the scientific hypothesis that dual inhibition of TYK2 and JAK1 could offer a superior efficacy profile compared to more selective agents.[1] Following preclinical characterization, Pfizer initiated a broad and ambitious clinical development program to explore the therapeutic potential of Brepocitinib across a wide spectrum of inflammatory conditions.

This early-stage program included multiple Phase 1 studies to establish the drug's safety, tolerability, and pharmacokinetic profile in healthy volunteers.[16] Subsequently, Pfizer launched a comprehensive Phase 2 program to evaluate efficacy in several large-market and specialty indications. This included trials in plaque psoriasis (oral and topical formulations), psoriatic arthritis, ulcerative colitis, Crohn's disease, alopecia areata, vitiligo, and atopic dermatitis.[11] This "multi-shot" approach is a common strategy employed by large pharmaceutical companies to identify the indication(s) where a promising new molecule has the optimal combination of efficacy, safety, and commercial viability. As will be detailed later, these Phase 2 studies consistently generated positive results, demonstrating that Brepocitinib was a clinically active agent across these diverse pathologies.

5.2 Strategic Pivot under Priovant Therapeutics

Despite the positive Phase 2 data generated by Pfizer, a significant strategic shift occurred when Pfizer licensed the global development rights for oral Brepocitinib and the U.S./Japan rights for topical Brepocitinib to Priovant Therapeutics, a new company formed in partnership with Roivant Sciences.[10] This move marked a pivotal change in the drug's development trajectory.

The rationale behind this strategic repositioning appears to be rooted in the highly competitive nature of the markets for the initial indications. While Brepocitinib demonstrated efficacy, its safety profile was largely consistent with the existing JAK inhibitor class, offering little differentiation. In therapeutic areas like psoriasis, psoriatic arthritis, and ulcerative colitis—which are dominated by highly effective and relatively safe biologic therapies and other approved JAK inhibitors—the commercial and regulatory bar for a new entrant is exceptionally high. A new drug must typically demonstrate clear superiority in efficacy or a significantly improved safety profile to gain market share.

Priovant's strategy, in contrast, has been to focus development on severe, high-unmet-need orphan and specialty autoimmune diseases.[10] In these areas, such as Dermatomyositis (DM) and Non-Infectious Uveitis (NIU), there are few, if any, approved targeted therapies, and the patient need for effective treatments is profound.[17] In this context, Brepocitinib's potent, broad-spectrum immunomodulatory mechanism could be transformative. The risk-benefit calculation is fundamentally different; a safety profile that might be a competitive disadvantage in psoriasis could be highly acceptable for a debilitating orphan disease with no other options. This strategic pivot was not a retreat from a failed drug, but a calculated business decision to place a clinically active asset into a therapeutic environment where its value could be maximized and its path to approval was clearer.

5.3 Overview of the Global Clinical Trial Landscape

Brepocitinib has been one of the most extensively studied investigational JAK inhibitors. To date, it has been administered to over 1,400 subjects across more than 14 completed Phase 1 and Phase 2 studies.[10] This vast body of clinical data provides a robust understanding of its efficacy signals and safety profile. The program has spanned multiple continents, with clinical trial sites located across North America, Europe, and Asia.[1]

Under Priovant's stewardship, the program has advanced into the late stages of development for its prioritized indications. A global Phase 3 registrational study in Dermatomyositis (VALOR) has completed enrollment, and a Phase 3 program for Non-Infectious Uveitis is expected to be initiated by the end of 2024.[31] Concurrently, development has been formally discontinued for a number of indications that were explored by Pfizer, including plaque psoriasis, psoriatic arthritis, ulcerative colitis, alopecia areata, and systemic lupus erythematosus.[17] Table 4 provides a high-level summary of the major clinical trials and the development status for each key indication.

Indication	Key Trial ID (NCT)	Highest Phase Reached	Current Development Status (as of late 2024)	Developing Entity
Dermatomyositis	NCT05437263 (VALOR)	Phase 3	Active	Priovant Therapeutics
Non-Infectious Uveitis	NCT05523765 (NEPTUNE)	Phase 2	Active (Phase 3 planned)	Priovant Therapeutics
Cutaneous Sarcoidosis	NCT06978725 (BEACON)	Phase 2	Active	Priovant Therapeutics
Psoriatic Arthritis	NCT03963401	Phase 2	Discontinued	Pfizer / Priovant
Plaque Psoriasis (Oral)	NCT02969018	Phase 2	Discontinued	Pfizer / Priovant
Ulcerative Colitis	NCT02958865 (VIBRATO)	Phase 2	Discontinued	Pfizer / Priovant
Crohn's Disease	NCT03395184	Phase 2	Discontinued	Pfizer / Priovant
Alopecia Areata	NCT02974868 (ALLEGRO)	Phase 2	Discontinued	Pfizer / Priovant
Hidradenitis Suppurativa	NCT04493502	Phase 2	Discontinued	Pfizer / Priovant
Systemic Lupus Erythematosus	N/A	Phase 2	Discontinued	Priovant Therapeutics
Atopic Dermatitis (Topical)	NCT03903822	Phase 2	Discontinued	Pfizer / Priovant
Table 4: Summary of Major Phase II/III Clinical Trials for Brepocitinib

6.0 Efficacy and Safety Analysis by Therapeutic Indication

The clinical development program for Brepocitinib has generated a wealth of efficacy and safety data across a diverse range of autoimmune diseases. An indication-by-indication analysis reveals a pattern of consistent clinical activity, which, when viewed alongside the strategic decisions to advance or discontinue each program, provides a nuanced picture of the drug's therapeutic potential and commercial positioning.

6.1 Dermatomyositis (DM) and Non-Infectious Uveitis (NIU): The Path to Registration

6.1.1 Pathophysiological Rationale and Unmet Need

Priovant's decision to prioritize Dermatomyositis and Non-Infectious Uveitis is strongly supported by both the scientific rationale and the significant unmet medical need in these conditions. Dermatomyositis is a severe, multi-organ idiopathic inflammatory myopathy characterized by debilitating and progressive muscle weakness and distinct, often disfiguring, skin lesions.[31] The disease can lead to significant disability, with many patients requiring mobility aids, and can also impact other organs, including the lungs, leading to interstitial lung disease.[6] A cardinal feature of DM pathogenesis is the overactivity of the Type I interferon signaling pathway, a pathway that is potently inhibited by Brepocitinib's dual TYK2/JAK1 mechanism.[6] The current treatment landscape is limited, with only steroidal products and intravenous immunoglobulin (IVIg) having received formal approval, leaving a substantial need for effective, targeted oral therapies.[31]

Similarly, non-infectious uveitis is a group of inflammatory conditions affecting the eye that represents the fourth leading cause of blindness among the working-age population in the developed world.[31] The disease is driven by pro-inflammatory cytokines, and the need for effective, steroid-sparing treatments is high.

6.1.2 Analysis of the Phase 3 VALOR and Phase 2 NEPTUNE Studies

Reflecting this strategic focus, Brepocitinib is being advanced in late-stage trials for both indications. The VALOR study (NCT05437263) is a global, Phase 3, randomized, placebo-controlled trial evaluating two dose levels of Brepocitinib in adults with active DM.[32] The primary objective is to assess efficacy based on the Total Improvement Score (TIS), a composite endpoint that measures changes across six core domains of disease activity.[30] With 241 subjects enrolled, VALOR is the largest interventional trial ever conducted in dermatomyositis, highlighting the medical community's interest in novel treatments.[31] Topline results are anticipated in 2025 and will be a pivotal event for the program.[30]

For NIU, the Phase 2 NEPTUNE study has been completed successfully, with primary endpoint data demonstrating a positive effect.[31] The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Brepocitinib for this indication, a move that underscores the seriousness of the condition and the drug's potential to address an unmet need.[30] Based on these results, Priovant plans to initiate a registrational, NDA-enabling Phase 3 program by the end of 2024.[31]

6.2 Psoriatic Arthritis (PsA): Analysis of Phase IIb Efficacy

6.2.1 Review of Trial NCT03963401: Design and Endpoints

Before the strategic pivot, Pfizer conducted a robust Phase IIb, randomized, placebo-controlled trial (NCT03963401) to evaluate Brepocitinib in 218 patients with active psoriatic arthritis.[36] The 52-week study randomized patients to receive once-daily oral doses of Brepocitinib (10 mg, 30 mg, or 60 mg) or placebo for an initial 16-week period, after which placebo patients were advanced to active treatment.[37] The primary endpoint was the proportion of patients achieving at least a 20% improvement in the American College of Rheumatology criteria (ACR20) at week 16.[37]

6.2.2 Efficacy Outcomes (ACR20/50/70, MDA) and Durability of Response

The trial met its primary endpoint with statistical significance. At week 16, the ACR20 response rates were 66.7% for the 30 mg group (p=0.0197) and 74.6% for the 60 mg group (p=0.0006), both of which were significantly superior to the 43.3% response rate observed in the placebo group.[37]

Furthermore, Brepocitinib demonstrated strong efficacy across multiple, more stringent secondary endpoints. Significantly higher response rates were also achieved for ACR50 and ACR70, as well as for skin-related outcomes like PASI75 and PASI90, and for the composite measure of Minimal Disease Activity (MDA).[37] The onset of action was rapid, with significant improvements seen as early as week 4.[38] Importantly, these high levels of response were maintained or continued to improve through the full 52 weeks of the study.[37] Despite these unequivocally positive and clinically meaningful results, the development of Brepocitinib for PsA was discontinued, a decision that underscores the challenging commercial landscape for this indication.[17]

Endpoint (at Week 16)	Placebo (%) (n=53)	Brepocitinib 30 mg QD (%) (n=54)	Brepocitinib 60 mg QD (%) (n=55)	p-value vs. Placebo (30mg / 60mg)
ACR20 Response	43.3	66.7	74.6	0.0197 / 0.0006
ACR50 Response	18.9	40.7	45.5	<0.05 / <0.01
ACR70 Response	7.5	20.4	23.6	<0.05 / <0.05
MDA Response	13.2	31.5	32.7	<0.05 / <0.05
PASI75 Response	25.0	58.8	76.9	<0.05 / <0.01
Table 5: Key Efficacy Outcomes from the Phase IIb Trial in Psoriatic Arthritis (NCT03963401) 37

6.3 Plaque Psoriasis (PsO): Oral and Topical Formulations

6.3.1 Efficacy of Oral Brepocitinib in Phase IIa Studies

In a Phase IIa study (NCT02969018) in patients with moderate-to-severe plaque psoriasis, oral Brepocitinib demonstrated significant efficacy.[13] The primary endpoint, change from baseline in Psoriasis Area and Severity Index (PASI) score at week 12, was met, with all active treatment groups showing statistically significant reductions compared to placebo.[42] The greatest effect was observed in the group receiving continuous treatment with 30 mg once daily.[42] As with PsA, despite this clear evidence of clinical activity, the oral program for psoriasis was discontinued.[17]

6.3.2 Evaluation of the Topical Cream Formulation

A topical formulation of Brepocitinib was developed to treat mild-to-moderate dermatological conditions, aiming for localized efficacy with minimal systemic risk.[23] In a Phase IIb trial in patients with mild-to-moderate atopic dermatitis (NCT03903822), the topical cream was successful, leading to significant improvements in Eczema Area and Severity Index (EASI) scores.[43] However, in a parallel Phase IIb study in patients with mild-to-moderate plaque psoriasis, the results were disappointing. While the topical cream was well tolerated, it was not deemed sufficiently effective in the current formulation and at the doses evaluated to treat the signs and symptoms of psoriasis.[44]

6.4 Inflammatory Bowel Disease (Ulcerative Colitis & Crohn's Disease)

6.4.1 Review of the Phase IIb VIBRATO Study in UC

The VIBRATO study (NCT02958865) was a Phase IIb, double-blind, umbrella study that evaluated Brepocitinib (10, 30, and 60 mg QD) and another investigational agent against placebo for an 8-week induction period in patients with moderate-to-severe ulcerative colitis.[1] The study successfully met its primary endpoint. Treatment with Brepocitinib resulted in a dose-dependent and statistically significant reduction in the total Mayo Score at week 8 compared to placebo.[46] The placebo-adjusted mean change from baseline was -1.8 for the 10 mg dose, -2.3 for the 30 mg dose, and -3.2 for the 60 mg dose (all statistically significant).[47] Significant improvements were also seen in key secondary endpoints, including rates of clinical remission, endoscopic improvement, and mucosal healing.[46] Despite these strong efficacy signals, development for UC was also discontinued.[17]

6.4.2 Efficacy Signals in Crohn's Disease

Brepocitinib was also evaluated in a Phase 2a study in patients with moderate-to-severe Crohn's disease (NCT03395184).[1] Positive results were generated in this trial as well, but this indication was similarly deprioritized and discontinued by the developers.[17]

6.5 Dermatological Indications: Alopecia Areata and Hidradenitis Suppurativa

6.5.1 Efficacy in Alopecia Areata (SALT Score Improvements)

In the Phase 2a ALLEGRO trial (NCT02974868), Brepocitinib demonstrated remarkable efficacy in patients with moderate-to-severe alopecia areata, a condition characterized by autoimmune-mediated hair loss.[50] The primary endpoint was the change from baseline in the Severity of Alopecia Tool (SALT) score at week 24. Brepocitinib treatment resulted in a least-squares mean difference from placebo of 31.1 in SALT score change, a highly significant result (

p<0.0001).[51] A key secondary endpoint, the proportion of patients achieving at least a 30% improvement in SALT score (SALT30), was achieved by 64% of patients on Brepocitinib compared to just 2% on placebo.[51] Exploratory analyses from the trial's extension phase also suggested that some patients who had an inadequate response to another JAK inhibitor, ritlecitinib, could still achieve a clinical response after switching to Brepocitinib, hinting at potentially different mechanisms of response.[52] Nevertheless, this indication was also discontinued.[17]

6.5.2 Clinical Response in Hidradenitis Suppurativa (HS)

Hidradenitis suppurativa is a chronic, painful, and debilitating inflammatory skin disease with limited treatment options.[53] Brepocitinib was evaluated in a Phase 2a platform trial (NCT04493502) alongside two other kinase inhibitors against placebo.[55] At the 16-week primary endpoint, Brepocitinib (45 mg QD) was the only agent to demonstrate a statistically significant benefit. The Hidradenitis Suppurativa Clinical Response (HiSCR) rate was 51.9% in the Brepocitinib group, compared to 33.3% in the placebo group.[54] The other two inhibitors, zimlovisertib and ropsacitinib, were not significantly different from placebo, highlighting the specific activity of Brepocitinib in this disease.[55]

6.6 Systemic Lupus Erythematosus (SLE): A Case Study in Discontinuation

6.6.1 Trial Design and Rationale

Given Brepocitinib's potent inhibition of the Type I IFN pathway, a key driver of SLE pathogenesis, there was a strong scientific rationale for its development in this indication.[10] Priovant initiated a large, global Phase 2 study in patients with moderate-to-severe active SLE, which was designed to potentially serve as one of two registrational studies required for approval.[10]

6.6.2 Analysis of the High Placebo Response and Strategic Implications

In late 2023, Roivant and Priovant announced that the trial had failed to meet its primary endpoint: a statistically significant improvement in the SLE Responder Index (SRI-4) at week 52 compared to placebo.[35] The reason provided for the failure was not a lack of drug activity. On the contrary, the companies stated that the active arm of the trial produced some of the highest SRI-4 responder rates ever observed in a major lupus study.[35] The failure was attributed to an unprecedentedly high placebo response rate, which made it impossible to demonstrate a statistically significant difference between the drug and placebo.[35]

Lupus is notoriously challenging for clinical trials, and high placebo response rates have been the cause of many trial failures.[59] While the outcome was disappointing, it provided a clear "stop" signal for the program. Rather than investing further in a high-risk indication, Priovant made the strategic decision to discontinue the SLE program and conserve resources for the more promising DM and NIU programs.[35] This event, while a clinical trial failure, can be viewed as a successful de-risking of the overall development portfolio, clarifying the path forward and focusing investment on assets with a higher probability of success.

7.0 Integrated Safety and Tolerability Profile

The safety and tolerability of Brepocitinib have been extensively evaluated across its numerous clinical trials, encompassing over 1,400 exposed subjects.[10] The overall safety profile is consistently described as being in line with that of other approved Janus kinase inhibitors, suggesting that it carries the known class-wide risks and will likely require similar monitoring and risk management strategies.[38]

7.1 Summary of Treatment-Emergent Adverse Events Across Studies

Across the various placebo-controlled trials, treatment-emergent adverse events (TEAEs) were generally more frequent in the Brepocitinib arms compared to placebo, with a majority of these events being mild to moderate in severity.[37]

Commonly reported TEAEs include infections, such as nasopharyngitis and upper respiratory tract infections.[61] Other reported events include acne, anemia, and elevations in serum creatinine levels.[62] In the Phase IIb trial for ulcerative colitis, infections were observed in 16.9% of patients receiving Brepocitinib, compared to 8.7% for ritlecitinib and 4.0% for placebo, suggesting a dose- and mechanism-related increase in infection risk.[46]

7.2 Analysis of Serious Adverse Events and Events of Special Interest

Serious adverse events (SAEs) have been reported in a minority of patients treated with Brepocitinib. In the 52-week PsA trial, 15 SAEs occurred in 12 participants (5.5%).[37] A key area of concern for the JAK inhibitor class is the risk of serious infections. Cases of serious infection, including herpes zoster and pneumonia, have been observed in patients receiving Brepocitinib.[37]

Other isolated SAEs have been reported, though their relationship to the study drug is often considered uncertain by investigators. For instance, two cases of rhabdomyolysis were reported in the brepocitinib group during the alopecia areata trial.[51] In the ulcerative colitis study, one thromboembolic event (peripheral artery thrombosis) occurred in a patient on Brepocitinib, and one death due to myocardial infarction occurred in a patient on a different study drug (ritlecitinib); both events were deemed unrelated to the study medication.[46] Importantly, in the large Phase IIb PsA trial, no major adverse cardiovascular events (MACE), venous thromboembolic events, or deaths were reported among patients treated with Brepocitinib over 52 weeks.[38]

7.3 Laboratory Parameter Changes and Monitoring Requirements

Consistent with the mechanism of action, changes in certain laboratory parameters are an expected pharmacological effect of Brepocitinib. The safety data from the PsA trial noted changes in select lab parameters consistent with the JAK inhibitor class.[38] These typically include potential effects on hematological parameters (e.g., hemoglobin, lymphocyte counts, neutrophil counts) and lipid profiles. Consequently, routine laboratory monitoring is a standard requirement in clinical trials with Brepocitinib and would be expected as part of any future product label. In studies of the topical formulation, where systemic exposure is much lower, no clinically significant trends in hematological parameters, creatine kinase, or liver function tests were observed.[61]

Adverse Event	Placebo (%)	Brepocitinib (All Doses, %)	Notes
Any Adverse Event	~60-68%	~61-75%	Higher incidence in active arms generally observed.
Infections (Overall)	~4-25%	~9-20%	Most common TEAE category.
Nasopharyngitis	Common	Common	Frequently reported across studies.
Herpes Zoster	Rare	~1-3%	Known risk for JAK inhibitors; serious cases reported.
Acne	Low	Higher	Noted particularly in dermatological trials.
Anemia	Low	Higher	Potential JAK2-mediated effect.
Increased Creatinine	Low	Higher	Common finding with JAK inhibitors.
Serious Adverse Events	~5-10%	~5-10%	Rates generally comparable to placebo in some studies.
Table 6: Integrated Summary of Common Treatment-Emergent Adverse Events Across Key Placebo-Controlled Studies (Representative Ranges) 37

7.4 Comparative Safety Within the JAK Inhibitor Class

The collective safety data for Brepocitinib positions it squarely within the established safety profile of the JAK inhibitor class. It does not appear to offer a significant safety advantage over existing approved agents. The modest selectivity against JAK2, as discussed in the pharmacodynamics section, likely contributes to this profile. At doses required for robust TYK2/JAK1 inhibition and clinical efficacy, the concomitant inhibition of JAK2 is sufficient to produce hematopoietic effects characteristic of less selective JAK inhibitors.

This lack of a differentiated safety profile is a critical factor in understanding the drug's development trajectory. For indications like psoriasis or ulcerative colitis, where numerous biologic therapies with excellent long-term safety records are available, a new oral agent with a JAK-class safety profile faces a significant competitive hurdle. The risk-benefit assessment by clinicians and payers in these markets would be challenging. However, in severe orphan diseases like dermatomyositis, where treatment options are limited and the disease itself carries high morbidity, the same risk-benefit profile can be viewed much more favorably. Priovant's strategic focus on these high-unmet-need areas is therefore not only a commercial decision but also a pragmatic alignment of the drug's established safety profile with a clinical context in which it is most likely to be deemed acceptable.

8.0 Strategic Analysis and Future Outlook

8.1 Synthesis of Brepocitinib's Risk-Benefit Profile

The extensive clinical data available for Brepocitinib allows for a well-defined assessment of its risk-benefit profile. The drug is unequivocally a potent and broadly effective oral immunomodulator. Its benefit has been clearly demonstrated through statistically significant and clinically meaningful outcomes in at least seven distinct autoimmune diseases, ranging from rheumatology and dermatology to gastroenterology. The consistency of this efficacy signal across diverse pathologies underscores the fundamental importance of the TYK2 and JAK1 signaling pathways in autoimmunity and validates the drug's mechanism of action.

The risks associated with Brepocitinib are equally well-characterized and are largely predictable, aligning closely with the known safety liabilities of the JAK inhibitor drug class. These include an increased risk of infections, particularly herpes zoster, and the potential for hematological and other laboratory abnormalities that necessitate routine monitoring. The critical conclusion from this synthesis is that the risk-benefit balance of Brepocitinib is highly context-dependent. In a therapeutic area with many safe and effective alternatives, its risk profile presents a competitive disadvantage. In a therapeutic area with profound unmet need and few or no approved targeted therapies, its potent efficacy presents a compelling therapeutic opportunity.

8.2 Competitive Landscape and Positioning in Key Indications

The future of Brepocitinib now rests on its performance in its two lead indications: Dermatomyositis and Non-Infectious Uveitis. In both areas, the competitive landscape is far more favorable than in the crowded markets it has exited.

In Dermatomyositis, the current standard of care often relies on high-dose corticosteroids and immunosuppressants, with IVIg being one of the few approved therapies.[6] There is a significant need for a convenient, effective, oral, steroid-sparing agent. If the Phase 3 VALOR study is successful, Brepocitinib could be positioned as a first-in-class oral TYK2/JAK1 inhibitor and a transformative new standard of care for patients with moderate-to-severe DM. Its primary competitors would be other investigational agents and the off-label use of other immunomodulators.

Similarly, in Non-Infectious Uveitis, treatment often involves local or systemic corticosteroids and conventional immunosuppressants, all of which carry significant long-term toxicities. The market is dominated by a single approved biologic (adalimumab). An effective oral agent like Brepocitinib could capture a significant share of this market, particularly for patients requiring systemic therapy. The FDA's granting of Fast Track designation signals a recognized unmet need and a potentially streamlined regulatory path.[30]

8.3 Future Research Directions and Unanswered Questions

Upon potential approval in DM and/or NIU, several strategic questions will emerge for Priovant. One key direction would be to reconsider some of the discontinued indications as potential label-expansion opportunities. For example, the strong efficacy data in Hidradenitis Suppurativa, another dermatological disease with high unmet need, could make it an attractive target for a post-approval Phase 3 study.

Further research will also be needed to better understand the long-term safety profile of Brepocitinib beyond the 52-week duration of most current trials. Post-marketing surveillance and long-term extension studies will be crucial for monitoring for any rare but serious adverse events. Additionally, there is an opportunity for translational research to identify biomarkers that could predict which patients are most likely to respond to Brepocitinib or are at higher risk for adverse events. Such a personalized medicine approach could further optimize its risk-benefit profile and solidify its place in the therapeutic armamentarium.

8.4 Concluding Assessment of Therapeutic Potential

Brepocitinib is a molecule with a complex and illuminating history. It is a potent, clinically active drug whose scientific promise has been repeatedly validated in Phase 2 trials. Its journey illustrates a critical reality of modern drug development: clinical success does not guarantee commercial or development success. The decision by Pfizer, and subsequently Priovant, to steer the drug away from large, competitive markets and toward niche, high-unmet-need orphan indications was a necessary and astute strategic maneuver. This repositioning has given a powerful but undifferentiated asset a clear and viable, albeit narrower, path to market.

The ultimate therapeutic potential of Brepocitinib will be defined by the outcomes of its ongoing and planned Phase 3 programs. The topline data from the VALOR study in Dermatomyositis, expected in 2025, represents the single most important value inflection point for the program. A positive result would not only validate the strategic pivot but would also provide a much-needed new therapeutic option for patients with a debilitating disease. Success in Non-Infectious Uveitis would further solidify its position as a valuable therapeutic agent for severe autoimmune conditions. Brepocitinib stands as a testament to the importance of strategic development, where finding the right disease for a drug can be as critical as discovering the right drug for a disease.

Works cited

1. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune ..., accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30113844/
2. Brepocitinib | C18H21F2N7O | CID 118878093 - PubChem, accessed August 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Brepocitinib
3. Definition of brepocitinib - NCI Drug Dictionary, accessed August 27, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/brepocitinib
4. What is Brepocitinib used for? - Patsnap Synapse, accessed August 27, 2025, https://synapse.patsnap.com/article/what-is-brepocitinib-used-for
5. pubchem.ncbi.nlm.nih.gov, accessed August 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Brepocitinib#:~:text=Upon%20oral%20administration%2C%20brepocitinib%20selectively,caused%20by%20certain%20immunological%20diseases.
6. Review Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis, accessed August 27, 2025, https://www.clinexprheumatol.org/article.asp?a=21096
7. Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale - ACR Meeting Abstracts, accessed August 27, 2025, https://acrabstracts.org/abstract/brepocitinib-for-the-treatment-of-dermatomyositis-pharmacologic-and-clinical-rationale/
8. Brepocitinib (PF-06700841) | JAK1/TYK2 Inhibitor | MedChemExpress, accessed August 27, 2025, https://www.medchemexpress.com/PF-06700841.html
9. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan - ACS Publications, accessed August 27, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00917
10. Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus, accessed August 27, 2025, https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing
11. Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis, accessed August 27, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis
12. Brepocitinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 27, 2025, https://synapse.patsnap.com/drug/a9008e10ca084f3db9d6315c6458d6f9
13. Brepocitinib - Wikipedia, accessed August 27, 2025, https://en.wikipedia.org/wiki/Brepocitinib
14. Brepocitinib (PF-06700841) | Safety Data Sheet - Selleck Chemicals, accessed August 27, 2025, https://www.selleckchem.com/msds/MSDS_S8804.pdf
15. Pfizer Pipeline, accessed August 27, 2025, https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_02FEB2021.pdf?VersionId=4O6sbapaG3_7G8fCeBygOtqH9lENo.bt
16. (PDF) Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients, accessed August 27, 2025, https://www.researchgate.net/publication/363194373_Population_Pharmacokinetics_of_Oral_Brepocitinib_in_Healthy_Volunteers_and_Patients
17. Brepocitinib - Priovant Therapeutics - AdisInsight, accessed August 27, 2025, https://adisinsight.springer.com/drugs/800041773
18. PF-06700841 tosylate salt ≥98% (HPLC) | Sigma-Aldrich, accessed August 27, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/pz0345
19. Brepocitinib (PF-06700841) | 98.10%(HPLC) | JAK inhibitor - Selleck Chemicals, accessed August 27, 2025, https://www.selleckchem.com/products/pf-06700841.html
20. Brepocitinib (PF-06700841) | CAS NO.:1883299-62-4 | GlpBio, accessed August 27, 2025, https://www.glpbio.com/brepocitinib-pf-06700841.html
21. (PDF) A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a C‐microdose approach - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/370771146_A_phase_1_study_to_investigate_the_absorption_distribution_metabolism_and_excretion_of_brepocitinib_in_healthy_males_using_a_C-microdose_approach
22. Brepocitinib free base | CAS# 1883299-62-4 | JAK1 Inhibitor - MedKoo Biosciences, accessed August 27, 2025, https://www.medkoo.com/products/34935
23. Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11024034/
24. BREPOCITINIB - Inxight Drugs, accessed August 27, 2025, https://drugs.ncats.io/substance/3X8387Q25N
25. www.guidetopharmacology.org, accessed August 27, 2025, [https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10459#:~:text=Comment%3A%20Brepocitinib%20(PF%2D06700841,Type%201%20ATP%20site%20inhibitor.](https://www.google.com/url?q=https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId%3D10459%23:~:text%3DComment%253A%2520Brepocitinib%2520(PF%252D06700841,Type%25201%2520ATP%2520site%2520inhibitor.&sa=D&source=editors&ust=1756234466014246&usg=AOvVaw3_fxabJqhdB5sd7z5DYHSp)
26. Pharmacokinetics: Definition & Use in Drug Development - Allucent, accessed August 27, 2025, https://www.allucent.com/resources/blog/what-pharmacokinetics-and-adme
27. Protein Kinase Inhibitors | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/categories/protein-kinase-inhibitors
28. Brepocitinib Completed Phase 1 Trials for Psoriasis Vulgaris (Plaque Psoriasis) - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB15003/clinical_trials?conditions=DBCOND0070073&phase=1&status=completed
29. Pfizer Pipeline, accessed August 27, 2025, https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_23Apr2019.pdf
30. Priovant mulls broad autoimmune indications for brepocitinib - Clinical Trials Arena, accessed August 27, 2025, https://www.clinicaltrialsarena.com/news/priovant-mulls-broad-autoimmune-indications-for-brepocitnib/
31. Priovant Therapeutics Announces Completion of Enrollment in ..., accessed August 27, 2025, https://www.prnewswire.com/news-releases/priovant-therapeutics-announces-completion-of-enrollment-in-global-phase-3-study-evaluating-brepocitinib-in-dermatomyositis-valor-302208124.html
32. A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis (VALOR) - ClinicalTrials.gov, accessed August 27, 2025, https://clinicaltrials.gov/study/NCT05437263
33. A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis - Mayo Clinic, accessed August 27, 2025, https://www.mayo.edu/research/clinical-trials/cls-20542769
34. A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis, accessed August 27, 2025, https://www.clinicaltrials.gov/study/NCT05437263
35. Roivant and Priovant Announce Results from Phase 2 Study of Oral ..., accessed August 27, 2025, https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-announce-results-phase-2-study-oral/
36. Brepocitinib Completed Phase 2 Trials for Psoriatic Arthritis Treatment | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB15003/clinical_trials?conditions=DBCOND0028320&phase=2&purpose=treatment&status=completed
37. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active ..., accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/37194394/
38. Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial - ACR Meeting Abstracts, accessed August 27, 2025, https://acrabstracts.org/abstract/efficacy-and-safety-of-brepocitinib-tyrosine-kinase-2-janus-kinase-1-inhibitor-for-the-treatment-of-active-psoriatic-arthritis-results-from-a-phase-2b-randomized-controlled-trial/
39. Brepocitinib shows promise in phase 2 trial for psoriatic arthritis - MDEdge, accessed August 27, 2025, https://www.mdedge.com/content/brepocitinib-shows-promise-phase-2-trial-psoriatic-arthritis
40. Brepocitinib Improves Psoriatic Arthritis Outcomes at 16, 52 Weeks - HCPLive, accessed August 27, 2025, https://www.hcplive.com/view/brepocitinib-psoriatic-arthritis-outcomes-16-52-weeks
41. Does brepocitinib benefit patients with psoriatic arthritis? - Wiley Newsroom - Q4 Inc., accessed August 27, 2025, https://johnwiley2020news.q4web.com/press-releases/press-release-details/2023/Does-brepocitinib-benefit-patients-with-psoriatic-arthritis/default.aspx
42. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis ..., accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/32311398/
43. Brepocitinib Completed Phase 2 Trials for Atopic Dermatitis Treatment | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB15003/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=treatment&status=completed
44. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study | British Journal of Dermatology | Oxford Academic, accessed August 27, 2025, https://academic.oup.com/bjd/article/189/1/33/7087205
45. Brepocitinib Completed Phase 2 Trials for Ulcerative Colitis Treatment | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB15003/clinical_trials?conditions=DBCOND0029012&phase=2&purpose=treatment&status=completed
46. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study | Request PDF - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/366935825_Oral_Ritlecitinib_and_Brepocitinib_for_Moderate-to-Severe_Ulcerative_Colitis_Results_From_a_Randomized_Phase_2b_Study
47. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/36623678/
48. Two Novel JAK Inhibitors Show Promise in Ulcerative Colitis - Medscape, accessed August 27, 2025, https://www.medscape.com/viewarticle/986896
49. Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10441644/
50. Brepocitinib Completed Phase 2 Trials for Alopecia Areata (AA) Treatment - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB15003/clinical_trials?conditions=DBCOND0071530&phase=2&purpose=treatment&status=completed
51. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/350218888_A_phase_2a_randomized_placebo-controlled_study_to_evaluate_the_efficacy_and_safety_of_the_oral_Janus_kinase_inhibitors_ritlecitinib_and_brepocitinib_in_alopecia_areata_24-week_results
52. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial - PubMed Central, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9579791/
53. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future, accessed August 27, 2025, https://www.actasdermo.org/es-narrative-review-update-on-biologic-articulo-S0001731023003551
54. Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/378106569_Brepocitinib_Zimlovisertib_and_Ropsacitinib_in_Hidradenitis_Suppurativa
55. RCT Results: Does Brepocitinib Improve Symptoms of Hidradenitis Suppurativa?, accessed August 27, 2025, https://www.obgproject.com/2024/03/26/rct-results-does-brepocitinib-improve-symptoms-of-hidradenitis-suppurativa/
56. evolutionary tale on clinical trials in hidradenitis suppurativa | British Journal of Dermatology, accessed August 27, 2025, https://academic.oup.com/bjd/article/192/Supplement_1/i15/7997104
57. Phase 2 Study of Oral Brepocitinib for Systemic Lupus Erythematosus Fails, accessed August 27, 2025, https://www.lupus.org/news/phase-2-study-of-oral-brepocitinib-for-systemic-lupus-erythematosus-fails
58. Brepocitinib fails to show benefits beyond placebo in Phase 2 trial - Lupus News Today, accessed August 27, 2025, https://lupusnewstoday.com/news/brepocitinib-fails-show-benefits-beyond-placebo-phase-2-trial/
59. Roivant ends longshot lupus program after phase 2 fail - Fierce Biotech, accessed August 27, 2025, https://www.fiercebiotech.com/biotech/roivant-ends-long-shot-lupus-program-after-phase-2-fail
60. Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials | PLOS One - Research journals, accessed August 27, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0320179
61. Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study* | British Journal of Dermatology | Oxford Academic, accessed August 27, 2025, https://academic.oup.com/bjd/article/187/6/878/6972541
62. Brepocitinib Shows Promising Results for Treatment of Cicatricial Alopecia, accessed August 27, 2025, https://www.dermatologytimes.com/view/brepocitinib-shows-promising-results-for-treatment-of-cicatricial-alopecia